Stock listing
NASDAQ:ONCY Oncolytics Biotech Inc. Stock
Home listing (NASDAQ) of Oncolytics Biotech Inc.
Follow Oncolytics Biotech Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ONCY
$0.35 USD -0.04 (-10.4%)
Close on Nov 20, 2026
- Day range
- $0.34 – $0.389 USDNov 20, 2026
- Volume
- 1.10M sharesNov 20, 2026
- Market cap
- $47.66M USDAt the close on Nov 20, 2026 · price × 136.1M shares outstanding
- 52-week range
- $0.333 – $1.30 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $672,271 USDMedian day 858,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ONCY · Home | $0.35 USD | -0.04 (-10.4%) | 1,096,588 | $0.38 | $0.389 | $0.34 | $0.391 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ONCY · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.35 | -0.04 | -10.4% | $0.38 | $0.389 | $0.34 | 1,096,588 | |
| $0.391 | -0.05 | -11.3% | $0.443 | $0.46 | $0.39 | 1,697,693 | |
| $0.44 | +0.058 | +15.1% | $0.39 | $0.445 | $0.377 | 2,185,488 | |
| $0.383 | +0.043 | +12.5% | $0.334 | $0.393 | $0.333 | 1,587,161 | |
| $0.34 | -0.03 | -8.1% | $0.371 | $0.376 | $0.337 | 1,326,598 | |
| $0.37 | 0.00 | 0.0% | $0.38 | $0.39 | $0.34 | 1,263,700 | |
| $0.37 | -0.04 | -9.8% | $0.41 | $0.42 | $0.37 | 817,100 | |
| $0.41 | +0.03 | +7.9% | $0.40 | $0.42 | $0.37 | 1,495,800 | |
| $0.38 | -0.03 | -7.3% | $0.41 | $0.42 | $0.38 | 542,500 | |
| $0.41 | -0.03 | -6.8% | $0.45 | $0.46 | $0.38 | 1,138,900 | |
| $0.44 | -0.01 | -2.2% | $0.46 | $0.46 | $0.43 | 512,400 | |
| $0.45 | +0.03 | +7.1% | $0.43 | $0.46 | $0.38 | 2,857,800 | |
| $0.42 | +0.03 | +7.7% | $0.41 | $0.44 | $0.39 | 873,200 | |
| $0.39 | -0.01 | -2.5% | $0.40 | $0.41 | $0.38 | 553,700 | |
| $0.40 | -0.03 | -7.0% | $0.42 | $0.43 | $0.39 | 844,400 | |
| $0.43 | 0.00 | 0.0% | $0.42 | $0.43 | $0.41 | 764,200 | |
| $0.43 | -0.01 | -2.3% | $0.44 | $0.45 | $0.43 | 607,300 | |
| $0.44 | -0.02 | -4.3% | $0.46 | $0.46 | $0.43 | 2,190,100 | |
| $0.46 | -0.01 | -2.1% | $0.47 | $0.50 | $0.46 | 859,300 | |
| $0.47 | -0.03 | -6.0% | $0.51 | $0.52 | $0.47 | 710,300 | |
| $0.50 | 0.00 | 0.0% | $0.51 | $0.51 | $0.49 | 375,800 | |
| $0.50 | -0.01 | -2.0% | $0.50 | $0.52 | $0.50 | 405,600 | |
| $0.51 | +0.01 | +2.0% | $0.50 | $0.52 | $0.49 | 771,600 | |
| $0.50 | 0.00 | 0.0% | $0.51 | $0.52 | $0.49 | 1,198,100 | |
| $0.50 | 0.00 | 0.0% | $0.51 | $0.55 | $0.49 | 690,500 | |
| $0.50 | -0.05 | -9.1% | $0.55 | $0.55 | $0.49 | 1,336,600 | |
| $0.55 | +0.01 | +1.9% | $0.55 | $0.59 | $0.52 | 1,300,700 | |
| $0.54 | +0.05 | +10.2% | $0.50 | $0.56 | $0.44 | 3,155,000 | |
| $0.49 | +0.02 | +4.3% | $0.49 | $0.50 | $0.45 | 4,202,500 | |
| $0.47 | -0.09 | -16.1% | $0.57 | $0.59 | $0.44 | 3,317,400 | |
| $0.56 | +0.02 | +3.7% | $0.55 | $0.57 | $0.53 | 1,459,000 | |
| $0.54 | -0.06 | -10.0% | $0.60 | $0.61 | $0.54 | 1,122,200 | |
| $0.60 | 0.00 | 0.0% | $0.59 | $0.61 | $0.58 | 669,000 | |
| $0.60 | 0.00 | 0.0% | $0.60 | $0.61 | $0.58 | 858,500 | |
| $0.60 | -0.03 | -4.8% | $0.64 | $0.64 | $0.58 | 1,936,400 | |
| $0.63 | -0.01 | -1.6% | $0.65 | $0.65 | $0.62 | 609,300 | |
| $0.64 | -0.03 | -4.5% | $0.67 | $0.68 | $0.63 | 689,800 | |
| $0.67 | 0.00 | 0.0% | $0.68 | $0.68 | $0.65 | 867,000 | |
| $0.67 | +0.01 | +1.5% | $0.67 | $0.68 | $0.66 | 779,000 | |
| $0.66 | -0.02 | -2.9% | $0.68 | $0.72 | $0.66 | 1,129,200 | |
| $0.68 | 0.00 | 0.0% | $0.69 | $0.69 | $0.67 | 822,000 | |
| $0.68 | 0.00 | 0.0% | $0.68 | $0.69 | $0.64 | 1,213,700 | |
| $0.68 | -0.03 | -4.2% | $0.73 | $0.73 | $0.66 | 1,890,900 | |
| $0.71 | -0.06 | -7.8% | $0.76 | $0.78 | $0.71 | 2,075,200 | |
| $0.77 | 0.00 | 0.0% | $0.77 | $0.79 | $0.76 | 693,300 | |
| $0.77 | 0.00 | 0.0% | $0.78 | $0.78 | $0.76 | 491,500 | |
| $0.77 | 0.00 | 0.0% | $0.78 | $0.80 | $0.77 | 594,200 | |
| $0.77 | -0.01 | -1.3% | $0.78 | $0.80 | $0.76 | 958,300 | |
| $0.78 | -0.03 | -3.7% | $0.83 | $0.84 | $0.78 | 903,100 | |
| $0.81 | +0.06 | +8.0% | $0.76 | $0.85 | $0.76 | 1,399,400 | |
| $0.75 | -0.02 | -2.6% | $0.77 | $0.77 | $0.73 | 1,198,300 | |
| $0.77 | -0.03 | -3.8% | $0.79 | $0.83 | $0.76 | 3,787,600 | |
| $0.80 | -0.01 | -1.2% | $0.80 | $0.83 | $0.79 | 741,300 | |
| $0.81 | -0.03 | -3.6% | $0.83 | $0.84 | $0.79 | 1,140,800 | |
| $0.84 | -0.02 | -2.3% | $0.84 | $0.85 | $0.83 | 463,700 | |
| $0.86 | -0.02 | -2.3% | $0.88 | $0.89 | $0.84 | 582,800 | |
| $0.88 | +0.04 | +4.8% | $0.85 | $0.91 | $0.84 | 1,585,400 | |
| $0.84 | 0.00 | 0.0% | $0.83 | $0.86 | $0.83 | 435,100 | |
| $0.84 | -0.02 | -2.3% | $0.85 | $0.87 | $0.83 | 428,900 | |
| $0.86 | +0.01 | +1.2% | $0.84 | $0.86 | $0.82 | 673,100 | |
| $0.85 | -0.01 | -1.2% | $0.86 | $0.87 | $0.84 | 569,100 | |
| $0.86 | 0.00 | 0.0% | $0.86 | $0.87 | $0.84 | 410,100 | |
| $0.86 | +0.02 | +2.4% | $0.85 | $0.87 | $0.84 | 775,300 | |
| $0.84 | 0.00 | 0.0% | $0.85 | $0.85 | $0.80 | 486,400 | |
| $0.84 | +0.04 | +5.0% | $0.80 | $0.85 | $0.80 | 539,900 | |
| $0.80 | -0.03 | -3.6% | $0.83 | $0.83 | $0.79 | 682,000 |
Splits
1 split · NASDAQ:ONCY · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-19 | Consolidation |
- Ticker
- NASDAQ:ONCY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 27 slides
Latest news
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC
Nov 13, 2026
Closed $0.37 (0.0%) on Nov 13, 2026
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma
Nov 11, 2026
Closed $0.37 (-9.8%) on Nov 12, 2026
Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
Nov 9, 2026
Closed $0.41 (-6.8%) on Nov 9, 2026
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
Nov 4, 2026
Closed $0.42 (+7.7%) on Nov 4, 2026
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
Oct 27, 2026
Closed $0.46 (-2.1%) on Oct 27, 2026
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
Oct 20, 2026
Closed $0.50 (0.0%) on Oct 20, 2026
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
Oct 14, 2026
Closed $0.54 (+10.2%) on Oct 14, 2026
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
Oct 12, 2026
Closed $0.49 (+4.3%) on Oct 13, 2026
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
Sep 29, 2026
Closed $0.67 (+1.5%) on Sep 29, 2026
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Sep 28, 2026
Closed $0.66 (-2.9%) on Sep 28, 2026
Oncolytics Biotech Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 37 in the last 12 months · 310 in all · newest Nov 13, 2026 · oldest 2016
- Calls
- 16 calls with a replay · 16 with a transcript · latest Aug 7, 2025
- Decks
- 30 decks · latest August 2026
Where Oncolytics Biotech Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ONCY · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ONCY | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $45.23M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.27
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Oncolytics Biotech Inc. · NASDAQ:ONCY | US$47.66M | US$45.23M | n/a | n/a | n/a | n/a | n/a | n/a | 1.27 |
| Acrivon Therapeutics, Inc. · NASDAQ:ACRV | US$49.35M | −US$26.60M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 2.09 |
| SYNTHAVERSE Spolka Akcyjna · GPW:SVE | US$48.68M | US$70.98M | n/a | 5.9× | n/a | 1.7× | −43.1% | 0.8× | n/a |
| Heron Therapeutics, Inc. · NASDAQ:HRTX | US$48.04M | US$156.3M | n/a | 1.1× | n/a | 9.8× | −14.5% | 26.8× | 1.93 |
| Helix BioPharma Corp. · TSX:HBP | US$47.94M | US$50.27M | n/a | n/a | n/a | 4.8× | n/a | 0.3× | 0.36 |
| THX Pharma · EURONEXT:ALTHX | US$47.23M | US$30.92M | n/a | n/a | n/a | 14.5× | n/a | 0.9× | n/a |
| FluoGuide A/S · OMXSTO:FLUO | US$47.17M | US$43.89M | n/a | 5,538× | n/a | 10.5× | n/a | 0.9× | n/a |
| Rafael Holdings, Inc. · NYSE:RFL | US$47.10M | US$25.00M | n/a | 28.6× | n/a | 0.7× | n/a | 0.0× | 0.92 |
| Bio-fd&c Co. Ltd · KRX:251120 | US$46.73M | US$5.29M | 9.8× | 0.4× | 0.9× | 0.9× | 32.8% | 0.0× | n/a |
| Andros Pharmaceuticals Co., Ltd. · TPEX:6917 | US$46.01M | US$35.88M | n/a | 213× | n/a | 3.1× | −969.3% | 0.0× | n/a |
| Werewolf Therapeutics, Inc. · NASDAQ:HOWL | US$46.01M | US$4.14M | n/a | n/a | n/a | 6.8× | n/a | 0.0× | 1.55 |
| Median of the others | US$47.20M | US$33.40M | 9.8× | 17.3× | 0.9× | 4.0× | −28.8% | 0.2× | 1.55 |
Forecasts
2 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.42 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.38 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jared Kelly | Chief Executive Officer & Director |
| Kirk Look | Chief Financial Officer |
| John McAdory | Chief Operating Officer |
| Jon Patton | Director of Investor Relations & Communication |
| Allison Hagerman | Chief Technology Officer |
| Andrew Aromando | Chief Business Officer |
| Thomas C. Heineman | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Wayne Pisano | Chair |
| Angela Holtham | Director |
| Bernd R. Seizinger | Director |
| Deborah M. Brown | Director |
| James T. Parsons | Director |
| Jared Kelly | Chief Executive Officer & Director |
| Jonathan Rigby | Director |
| Pat Andrews | Director |
| Steve Glover | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Oncolytics Biotech (NASDAQ:ONCY) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q1 2025 Earnings Call | Wed, May 14, 2025 · 4:30 PM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q4 2024 Earnings Call | Fri, Mar 07, 2025 · 8:30 AM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 8:30 AM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q2 2024 Earnings Call | Thu, Aug 01, 2024 · 4:30 PM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q1 2024 Earnings Call | Thu, May 09, 2024 · 4:30 PM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q4 2023 Earnings Call | Thu, Mar 07, 2024 · 4:30 PM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q3 2023 Earnings Call | Fri, Nov 03, 2023 · 8:30 AM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q2 2023 Earnings Call | Thu, Aug 10, 2023 · 12:00 PM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q1 2023 Earnings Call | Fri, May 05, 2023 · 8:30 AM ET | Replay |
All 16 calls
| Call | When | Status |
|---|---|---|
| Oncolytics Biotech (NASDAQ:ONCY) Q4 2022 Earnings Call | Fri, Mar 03, 2023 · 8:30 AM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q3 2022 Earnings Call | Mon, Nov 07, 2022 · 8:30 AM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q2 2022 Earnings Call | Thu, Aug 11, 2022 · 8:30 AM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q1 2022 Earnings Call | Thu, May 05, 2022 · 5:00 PM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q4 2021 Earnings Call | Thu, Mar 03, 2022 · 5:00 PM ET | Replay |
| Oncolytics Biotech (NASDAQ:ONCY) Q3 2021 Earnings Call | Fri, Nov 05, 2021 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · After close | −8.1% |
| Q2 2026 | Aug 12, 2026 · After close | −2.4% |
| Q1 2026 | May 14, 2026 · After close | −2.3% |
| Q4 2025 | Mar 5, 2026 | 0.0% |
| Q3 2025 | Nov 12, 2025 · After close | −4.8% |
| Q2 2025 | Aug 8, 2025 · Before open | −6.2% |
| Q1 2025 | May 7, 2025 · Before open | +1.6% |
| Q4 2024 | Mar 7, 2025 · Before open | −6.3% |
| Q3 2024 | Nov 12, 2024 · Before open | +3.7% |
| Q2 2024 | Aug 1, 2024 · After close | −1.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −5.7% |
| Q4 2023 | Mar 7, 2024 · After close | +1.0% |
| Q3 2023 | Nov 3, 2023 · Before open | −3.9% |
| Q2 2023 | Aug 14, 2023 · Before open | +1.0% |
| Q1 2023 | May 5, 2023 · Before open | +10.3% |
| Q4 2022 | Mar 3, 2023 · Before open | −5.4% |
| Q3 2022 | Nov 7, 2022 · Before open | +19.1% |
| Q2 2022 | Aug 11, 2022 · Before open | +0.0% |
| Q1 2022 | May 5, 2022 · After close | 0.0% |
| Q4 2021 | Mar 2, 2022 · After close | −5.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 27 slides | August 2026 |
| Investor Presentation (June 2026) | Investor deck | 27 slides | June 2026 |
| Investor Presentation (April 2026) | Investor deck | 26 slides | April 2026 |
| Investor Presentation (March 2026) | Investor deck | 23 slides | March 2026 |
| Investor Presentation (February 2026) | Investor deck | 23 slides | February 2026 |
| Investor Presentation (October 2025) | Investor deck | 21 slides | October 2025 |
| Investor Presentation (March 2025) | Investor deck | 42 slides | March 2025 |
| Investor Presentation (December 2024) | Investor deck | 43 slides | December 2024 |
| Investor Presentation (October 2024) | Investor deck | 41 slides | October 2024 |
| Investor Presentation (October 2024) | Investor deck | 43 slides | October 2024 |
All 30 decks
Financings
| Raise | Date |
|---|---|
| Common shares under equity line of credit (share purchase agreement) Cancelled: raise Buyers: Alumni (obligated to purchase up to US$20 million worth of common stock over a 15-month period); Alumni Capital Use of proceeds: Funding to progress pelareorep's clinical development toward key clinical milestones | Aug 8, 2025 |
| At-the-market programme of common shares Cancelled: Cantor Fitzgerald Dealers: Cantor Fitzgerald | Aug 8, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 70.0K | 298.6K | 301.1K | 360.6K | 332.7K | 485.6K | 95.4K | 90.8K | 162.2K | |
| Gross profit | -70.0K | -298.6K | -301.1K | -360.6K | -332.7K | -485.6K | -95.4K | -90.8K | -162.2K | |
| Research and development | 13.3M | 15.4M | 13.3M | 11.4M | 12.9M | 12.9M | 10.8M | 9.42M | 9.39M | 9.77M |
| Selling, general and administrative | 15.4M | 11.8M | 8.18M | 12.9M | 12.5M | 9.56M | 7.24M | 6.21M | 5.36M | |
| Operating income | -28.7M | -25.5M | -25.5M | -19.8M | -26.2M | -25.5M | -20.1M | -16.7M | -15.6M | -15.3M |
| Depreciation and amortization | 70.0K | 87.0K | 303.8K | 288.8K | 452.0K | 446.0K | 485.6K | 95.4K | 90.8K | 162.2K |
| EBITDA | -28.7M | -25.5M | -25.2M | -19.5M | -25.8M | -25.0M | -19.7M | -16.6M | -15.5M | -15.1M |
| Interest expense | 528.0K | 138.4K | 0 | 0 | 0 | 0 | 0 | |||
| Income before tax | -28.7M | -22.7M | -20.8M | -18.2M | -26.3M | -22.5M | -33.1M | -16.5M | -15.5M | -15.1M |
| Income tax | 79.0K | 95.0K | 73.1K | 61.9K | 49.0K | -2.95M | 12.4M | 548.0K | 141.5K | 9.37K |
| Net income | -28.8M | -22.8M | -20.9M | -18.3M | -26.3M | -22.5M | -45.6M | -17.0M | -15.6M | -15.1M |
| Earnings per share, basic | -0.30 | -0.30 | -0.31 | -0.32 | -0.49 | -0.56 | -2.06 | -1.06 | -1.12 | -1.20 |
| Earnings per share, diluted | -0.30 | -0.30 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.20M | 11.1M | 34.9M | 11.7M | 41.3M | 31.2M | 14.1M | 13.7M | 11.8M | 12.0M |
| Short-term investments | 3.38M | 20.5M | 1.36M | 30.4M | 13.1M | 0 | 0 | 2.09M | ||
| Receivables | 786.2K | 15.0K | 521.0K | 866.0K | 89.7K | 2.07M | 51.6K | 4.80M | 54.4K | |
| Inventory | 0 | 0 | 0 | |||||||
| Current assets | 6.84M | 12.4M | 38.2M | 35.7M | 44.9M | 33.7M | 18.9M | 14.5M | 17.8M | 14.4M |
| Property, plant and equipment | 228.0K | 286.0K | 652.0K | 976.3K | 609.1K | 727.5K | 412.7K | 333.4K | 320.0K | |
| Goodwill | 0 | 0 | 0 | |||||||
| Total assets | 7.58M | 13.4M | 38.8M | 37.3M | 45.9M | 34.3M | 19.7M | 14.9M | 18.2M | 14.8M |
| Accounts payable | 3.50M | 756.0K | 1.08M | 2.25M | 594.0K | 1.81M | 3.17K | 1.83M | 3.68M | 4.07M |
| Current liabilities | 6.10M | 4.88M | 4.24M | 3.94M | 2.69M | 2.71M | 12.9M | 2.81M | 5.23M | 4.07M |
| Long-term debt | 0 | 0 | 0 | |||||||
| Total debt | 772.5K | 423.0K | 373.0K | 655.0K | 402.1K | 506.3K | ||||
| Total liabilities | 11.4M | 10.1M | 11.3M | 10.8M | 9.78M | 9.59M | 19.8M | 8.67M | 9.87M | 4.07M |
| Shareholders' equity | -3.80M | 3.30M | 27.6M | 26.5M | 36.1M | 24.8M | -107.9K | 6.20M | 8.28M | 10.7M |
| Shares outstanding | 108.0M | 80.0M | 67.6M | 58.0M | 53.5M | 40.3M | 22.1M | 16.0M | 13.9M | 12.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -20.1M | -19.9M | -21.4M | -17.2M | -22.4M | -22.1M | -19.9M | -11.9M | -14.9M | -12.5M |
| Capital spending | -6.00K | -174.0K | -6.03K | -40.5K | -286.0K | -29.0K | -10.9K | -107.5K | -105.8K | -23.5K |
| Free cash flow | -20.1M | -20.1M | -21.5M | -17.2M | -22.7M | -22.1M | -19.9M | -12.0M | -15.0M | -12.5M |
| Cash from investing | -6.00K | -174.0K | 15.2M | -15.0M | -286.0K | -29.0K | -10.9K | -107.5K | 1.98M | -51.4K |
| Cash from financing | 14.1M | 5.03M | 24.1M | 8.99M | 33.0M | 39.8M | 21.0M | 13.3M | 12.8M | 956.1K |
| Dividends paid | 0 | 0 | 0 | |||||||
| Share buybacks | 13.3M | 12.8M | 6.18K | 302 | ||||||
| Change in cash | -5.88M | -15.3M | 17.5M | -21.8M | 10.0M | 17.1M | 448.1K | 1.86M | -198.2K | -12.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Current report | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| 8-K · Current report | Nov 4, 2026 | Current report | SEC |
| 8-K · Current report | Oct 27, 2026 | Current report | SEC |
| 8-K · Current report | Oct 20, 2026 | Current report | SEC |
| 8-K · Current report | Oct 14, 2026 | Current report | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Oct 6, 2026 | Meeting notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| DEF 14A · Proxy statement | Oct 6, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| 8-K · Current report | Sep 10, 2026 | Current report | SEC |
| 8-K · Current report | Aug 18, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 24, 2026 | Current report | SEC |
| 8-K · Current report | Jul 20, 2026 | Current report | SEC |
| 8-K · Current report | Jul 13, 2026 | Current report | SEC |
| 8-K · Current report | Jul 8, 2026 | Current report | SEC |
| 8-K · Current report | Jun 16, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| 8-K · Current report | May 22, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2026 | Current report | SEC |
| 8-K · Current report | Apr 27, 2026 | Current report | SEC |
| F-10POS | Apr 8, 2026 | Other filings | SEC |
| F-10POS | Apr 8, 2026 | Other filings | SEC |
| F-10POS | Apr 8, 2026 | Other filings | SEC |
| F-10POS | Apr 8, 2026 | Other filings | SEC |
| F-10POS | Apr 8, 2026 | Other filings | SEC |
| F-10POS | Apr 8, 2026 | Other filings | SEC |
| F-10POS | Apr 8, 2026 | Other filings | SEC |
| F-10POS | Apr 8, 2026 | Other filings | SEC |
| F-10POS | Apr 8, 2026 | Other filings | SEC |
| F-10POS | Apr 8, 2026 | Other filings | SEC |
| AW | Apr 8, 2026 | Other filings | SEC |
| AW | Apr 8, 2026 | Other filings | SEC |
| AW | Apr 8, 2026 | Other filings | SEC |
| AW | Apr 8, 2026 | Other filings | SEC |
| AW | Apr 8, 2026 | Other filings | SEC |
| AW | Apr 8, 2026 | Other filings | SEC |
| AW | Apr 8, 2026 | Other filings | SEC |
| AW | Apr 8, 2026 | Other filings | SEC |
| AW | Apr 8, 2026 | Other filings | SEC |
| AW | Apr 8, 2026 | Other filings | SEC |
| F-10POS | Apr 6, 2026 | Other filings | SEC |
| F-10POS | Apr 6, 2026 | Other filings | SEC |
| F-10POS | Apr 6, 2026 | Other filings | SEC |
| F-10POS | Apr 6, 2026 | Other filings | SEC |
| F-10POS | Apr 6, 2026 | Other filings | SEC |
| F-10POS | Apr 6, 2026 | Other filings | SEC |
| F-10POS | Apr 6, 2026 | Other filings | SEC |
| F-10POS | Apr 6, 2026 | Other filings | SEC |
| F-10POS | Apr 6, 2026 | Other filings | SEC |
| F-10POS | Apr 6, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 6, 2026 | Current report | SEC |
| 424B5 · Prospectus | Apr 6, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 6, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 6, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 2, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 1, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 1, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 1, 2026 | Material contract | SEC |
| F-10POS | Mar 31, 2026 | Other filings | SEC |
| F-10POS | Mar 31, 2026 | Other filings | SEC |
| F-10POS | Mar 31, 2026 | Other filings | SEC |
| F-10POS | Mar 31, 2026 | Other filings | SEC |
| F-10POS | Mar 31, 2026 | Other filings | SEC |
| F-10POS | Mar 31, 2026 | Other filings | SEC |
| F-10POS | Mar 31, 2026 | Other filings | SEC |
| F-10POS | Mar 31, 2026 | Other filings | SEC |
| F-10POS | Mar 31, 2026 | Other filings | SEC |
| F-10POS | Mar 31, 2026 | Other filings | SEC |
| S-8 POS | Mar 31, 2026 | Offer document | SEC |
| S-8 POS | Mar 31, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 31, 2026 | Offer document | SEC |
| S-3 · Registration statement | Mar 31, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 31, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2026 | Current report | SEC |
| 8-K · Current report | Mar 19, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| 8-K · Current report | Feb 24, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 4, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 15, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jan 14, 2026 | Current report | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 425 | Jan 9, 2026 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jan 7, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 2, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Dec 16, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 10, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Dec 9, 2025 | Current report | SEC |
| 424B3 · Prospectus | Dec 9, 2025 | Offer document | SEC |
| F-4/A | Dec 5, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 5, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Nov 20, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 19, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 4, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 28, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 20, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 17, 2025 | Current report | SEC |
| F-4 | Oct 17, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Oct 17, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Oct 10, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 29, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 16, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 8, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 2, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 2, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Aug 28, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Aug 27, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 27, 2025 | Other filings | SEC |
| F-3 · Registration statement | Aug 22, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Aug 11, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 8, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 8, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 8, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 8, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 5, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 29, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 23, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 22, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 16, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 10, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 8, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 8, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 30, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 11, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 23, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 14, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 14, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 8, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 24, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 10, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 10, 2025 | Current report | SEC |
| SUPPL | Apr 10, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Apr 10, 2025 | Current report | SEC |
| 20-F · Annual report | Mar 7, 2025 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Mar 7, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 25, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 19, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 18, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Feb 14, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 10, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 22, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 15, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 23, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 18, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 3, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 4, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 19, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 6, 2024 | Current report | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Oncolytics Biotech Inc.’s releases · as of Nov 13, 2026
- Common shares
- 136,140,469
- Fully diluted
- 136,140,469
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 136,140,469 | Nov 13, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 136,140,469 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Patricia S Andrews Other companies: Geron Corporation (Director · Since at least Mar 25, 2026); Crescent Biopharma, Inc. (Director · Jun 9, 2017 – May 1, 2024 · Past); Incyte Corporation (Chief Commercial Officer · Oct 21, 2008 – Jan 19, 2012 · Past) | Director · Since at least Jan 1, 2026 |
| Bernd R. Seizinger Other companies: Aprea Therapeutics, Inc. (Director · Since at least Oct 2, 2019); Aptose Biosciences Inc (Director · Sep 13, 2022 – Feb 5, 2024 · Past) | Director · Since at least Jan 1, 2026 |
| James Parsons Other companies: DiaMedica Therapeutics Inc. (Chairman of the Board · Since at least Dec 6, 2018); Trillium Therapeutics Inc (Chief Financial Officer · Jan 1, 2021 – Nov 17, 2021 · Past) | Director · Since at least Jan 1, 2026 |
| Jonathan Rigby Other companies: BioPlus Acquisition Corp (Chief Business Officer, Director · Dec 2, 2021 – Dec 2, 2021 · Past); SteadyMed Ltd (President and CEO, Director · Dec 28, 2017 – Aug 30, 2018 · Past) | Director · Since at least Jan 1, 2026 |
| Wayne Pisano Other companies: Altimmune, Inc. (Director · Since at least Aug 30, 2018); Provention Bio Inc (Director · Jul 3, 2018 – Apr 27, 2023 · Past) | Director · Since at least Jun 26, 2025 |
| Andrew Aromando Other companies: Ambrx Biopharma Inc. (Chief Operating Officer · Apr 28, 2023 – Mar 7, 2024 · Past) | Chief Business Officer · Since at least Jun 30, 2025 |
| John McAdory Other companies: CG Oncology, Inc. (EVP of Strategy and Operations · Jan 14, 2026 – Nov 5, 2026 · Past) | Chief Operating Officer · Since at least Jun 1, 2026 |
| Allison Hagerman | Chief Technology Officer · Since at least Nov 5, 2026 |
| Angela Holtham | Director · Since at least Nov 4, 2026 |
| Deborah M. Brown | Director · Since at least Jan 1, 2026 |
All 16 people
| Person | Seat |
|---|---|
| Jared Kelly | Chief Executive Officer & Director · Since at least Oct 27, 2026 |
| Jon Patton | Director of Investor Relations & Communication · Since at least Oct 27, 2026 |
| Kirk Look | Chief Financial Officer · Since at least Nov 5, 2026 |
| Pat Andrews | Director · Since at least Nov 5, 2026 |
| Steve Glover | Director · Since at least Jun 2, 2026 |
| Thomas C. Heineman | Chief Medical Officer · Since at least Jan 1, 2026 |
Log in to ask 6ix AI your own questions about Oncolytics Biotech Inc.